Replies to post #71312 on Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

no predictions...your call.

[TheMonolith]

Hitting a lot of radars this weekend and tomorrow will bring even more. CTIX will end up converting a lot of people who were going short into longs. They'll probably be here on the boards heavily by the end of the week. Lot of good people here to keep it relaxed and enjoy their arrival.

[TheDane]

What are you doing? Just pony up and if it drops buy more. I know you can do it.

[frrol]

There are always people shorting. I've done it (Blackberry). Even a 'good' stock will be shorted if a speculator thinks the share price has overshot. Those folks are quite valuable to a properly functioning securities market. If they "bash" a stock to push the price down, that is as illegal as a long "pumping" the stock. Ie, it's not. As for naked shorting, that is their broker's foul, not there's, and it is the SEC's job to enforce its laws. And my experience in investing has been that good companies and stocks go up in the long term, and that 99% of accusations of "naked shorting" are done out of sour-graping, ignorance, impatience, and other bad investing habits. You'll see it here, guarantee it. We're human.

[sox040713]

I think technical analysis applies less in biotechs than other types of stocks. That is why their SPs tend to be volatile and can be easily influenced by rumors and news of FDA actions. Clinical trial data and partnership deals are the main driver of course. Usually there will be a SP run-up near the result.

In the case of B, the run-up has started and is nowhere close to be done IMO. Leo has basically told us that the result is good after presenting the preliminary data. Last week’s close tells me that demands are much greater than supplies. Shorts who sold two weeks ago around $2 are looking at 34.5% increase since. Good luck trying to cover.

So when do the shorts arrive? Before or after B unblinded. At an all time high and RSI lofty.

[noretreat]

Shorts usually come in droves with uplisting. Right now the stock remains relatively difficult to short.